论文部分内容阅读
目的观察诺和锐30治疗初诊2型糖尿病的临床疗效及安全性。方法将60例初诊2型糖尿病患者随机分为诺和锐30组和诺和灵30R组各30例。诺和锐30组每日早晚餐前皮下注射诺和锐30;诺和灵30R组每日早晚餐前15～30min皮下注射诺和灵30R。结果两组患者胰岛素治疗后FBG、2hPBG及HbAlc水平均明显下降(P<0.01),诺和锐30组餐后血糖、糖化血红蛋白下降幅度更明显(P<0.05)。两组患者空腹血糖下降差异无统计学意义(P>0.05),但诺和锐30组空腹血糖下降幅度高于诺和灵30R组。诺和锐30组低血糖(<2.8mmol/L)发生率显著低于诺和灵30R组(P<0.05)。结论诺和锐30可模拟人胰岛素生理分泌模式,实现更佳降糖,且低血糖发生率低,为DM患者提供了方便、安全、灵活的治疗手段。
Objective To observe the clinical efficacy and safety of Novo-Rui 30 in newly diagnosed type 2 diabetes mellitus. Methods Sixty patients with newly diagnosed type 2 diabetes were randomly divided into three groups: noluolei 30 and noradren 30R. Nuoherui 30 group daily before and after meals subcutaneously before and after the meal Novocre 30; Novolin 30R daily morning and evening 15-30 min before the injection of Novolin 30R. Results The levels of FBG, 2h PBG and HbAlc in both groups were significantly decreased after insulin treatment (P <0.01). The decrease of postprandial blood glucose and glycosylated hemoglobin in Novo Rui 30 group was more obvious (P <0.05). The difference of fasting blood glucose between the two groups had no significant difference (P> 0.05), but the decrease of fasting blood glucose of Novo-Rui-30 group was higher than that of Norvuling 30R group. The incidence of hypoglycemia (<2.8 mmol / L) in Novo Rui 30 group was significantly lower than that of Norvuling 30R group (P <0.05). Conclusion Novo Rui 30 can simulate the physiological insulin secretion model, to achieve better hypoglycemic, and low incidence of hypoglycemia, DM patients provide a convenient, safe and flexible treatment.